AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 162 min read$RDNT

Forthuber Stephen M sold $2.6M of RDNT

Forthuber Stephen M (Pres & CEO-Eastern Operations) sold 44,067 shares of RadNet, Inc. (RDNT) at an average of $58.16 ($57.79–$58.61, $2.56M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Forthuber Stephen M
Published Jun 16, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RDNT
Bearish
medium confidence
Mentioned
$RDNT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDNTBearishLow
01

Why it matters

The disclosure provides a concrete, date-stamped insider sale amount and price range, which can influence short-term sentiment but does not introduce new operating or financial information.

02

Market read

Traders may monitor RDNT for continued insider selling or unusual volume, but the event alone is unlikely to drive a durable repricing.

03

What to watch

Because the article notes no 10b5-1 plan, traders may over-weight signal; also, insider sales can be tax-related and do not necessarily imply near-term earnings deterioration.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-16; sale executed 2026-06-15

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for RadNet, Inc.

Company-level read

Ticker impact

$RDNTBearishMedium confidence
Context

RadNet CEO-Eastern Operations sold $2.56M of RDNT shares via an open-market Form 4 on 2026-06-15 at ~$58.16 weighted avg.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling or other fundamentals emerge.

Evidence & confidence

The filing discloses a specific insider sale size/price and confirms it was not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but it does not change guidance, contracts, or financial results.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/earnings catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio rebalancing rather than a bearish view, especially since the filing provides no stated reason or linkage to fundamentals.

Key entities

  • issuer
    RadNet, Inc.

    Subject of the Form 4 insider transaction; CEO-Eastern Operations sold shares on 2026-06-15.

  • insider
    Forthuber Stephen M

    Officer (Pres & CEO-Eastern Operations) who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RDNT insider trading history →

Related articles

OCT 27
$RDNTHighAI 8/10

Truist reiterates Buy on RadNet stock after ONRAD acquisition

Truist Securities reiterated a Buy rating and $94 price target on RadNet (RDNT) after its $700M acquisition of ONRAD. The deal includes cash, shares, and an earnout. RadNet's stock trades at $73.77, with analysts citing growth potential. The company reported strong Q2 2026 results, raising guidance and prompting price target increases from multiple analysts.

investing.com2 min
OCT 27
HighAI 9/10

RadNet acquires ONRAD in $355m deal to broaden radiology provision

RadNet agreed to acquire ONRAD for $355m ($350m cash, $5m shares) with a potential $210m earnout. The deal, expected to close in early 2027, aims to expand RadNet's radiology services and address staffing shortages. RadNet plans to integrate ONRAD's teleradiology and staffing services with its AI-based solutions to improve efficiency and patient care. Jefferies analysts called it a 'sound transaction.'

medicaldevice-network.com2 min
SEP 16
$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

yahoo.com3 min
SEP 4
$RDNTMed

RadNet (RDNT) Posts Record Revenue But Profit Growth Lags

RadNet (RDNT) reported Q2 2026 revenue of $622.7M, up 25% YoY, and raised full-year guidance. Profit growth lagged, with net income falling to $7.5M from $14.5M YoY. Digital Health revenue grew 56.5%, but its EBITDA dropped 27.2%. Hedge fund ownership declined, while short interest remains high at 14.56%.

insidermonkey.com3 min